Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00809965 · ClinicalTrials.gov registry record · Phase 3
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
A Phase 3 study of Myocardial Infarction and Acute Coronary Syndrome, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 3
- Development phase
- 15,526
- Enrollment target
- 20
- Study locations
NCT00809965 is a Phase 3 study of Myocardial Infarction and Acute Coronary Syndrome that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 15,526 participants, above the 4,439-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (250% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT00809965, a Phase 3 study of Myocardial Infarction and Acute Coronary Syndrome, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 15,526 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular death, myocardial infarction, or stroke in patients with a recent acute coronary syndrome compared with placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Standard of care
- DRUG Rivaroxaban 2.5 mg
- DRUG Rivaroxaban 5 mg
Study Locations (20)
Florida
- - Jacksonville
- - Jupiter
- - Kissimmee
- - Miami
- - Ocala
- - Orlando
- - Ormond Beach
- - St. Petersburg
California
- - Anaheim
- - Burbank
- - Los Angeles
- - Mission Hills
- - San Diego
Alabama
- - Birmingham
- - Geneva
- - Mobile
Colorado
- - Aurora
- - Littleton
Georgia
- - Columbus
- - Rome
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15,526 participants |
| Start Date | 2008-11 |
| Est. Completion | 2011-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00809965
The ClinicalTrials.gov registry entry for NCT00809965 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 15,526 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 4,439-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (250% higher). The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Myocardial Infarction appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT00809965 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT00809965 about?
NCT00809965 is a clinical study titled "An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome". The purpose of this study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular death, myocardial infarction, or stroke in patients with a recent acute coronary syndrome compared with placebo.
What is the current status of trial NCT00809965?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 15,526 participants. The study started on 2008-11. Estimated completion is 2011-09.
What conditions does trial NCT00809965 study?
This clinical trial studies the following conditions: Myocardial Infarction, Acute Coronary Syndrome, Myocardial Ischemia, Unstable Angina.
What interventions are being tested in trial NCT00809965?
The interventions under investigation include: Placebo (DRUG), Standard of care (DRUG), Rivaroxaban 2.5 mg (DRUG), Rivaroxaban 5 mg (DRUG).
Who is sponsoring clinical trial NCT00809965?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00809965 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myocardial Infarction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging
COMPLETED · Phase 3
-
Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction
COMPLETED · Phase 3
-
Occluded Artery Trial (OAT)
COMPLETED · Phase 3
-
IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.
COMPLETED · Phase 3
-
Myocardial Ischemia and Transfusion Pilot
COMPLETED · Phase 3
-
Vitamin Therapy for Prevention of Stroke
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.